Experimental data across all four major ovarian cancer subtypes indicate that Mirk depletion enhances cisplatin responsiveness, even at low drug concentrations, suggesting that this approach may simultaneously improve therapeutic efficacy and reduce cisplatin-associated toxicities [17]. Here, DYRK1B is linked to ovarian cancer.